

American Society of Gene + Cell Therapy

Discovery of TSC-200-A02: A natural HPV16 E7-specific TCR-T cell therapy candidate for the treatment of HPV-positive solid tumors

Sonal Jangalwe, Daniel C Pollacksmith, Cisem Karaca, Shubhangi Kamalia, Mollie M Jurewicz, Kimberly M Cirelli, Alexandra L Luther, Hannah L Bader, Briana N Zimmerman, Tary Traore, Maytal Bowman, Andrew S Basinski, Anna M Labrozzi, Kenneth L Jahan, Sida Liao, Amy Virbasius, Kristen Murray, Lisa Nip, Christina E Lam, Livio Dukaj, Danielle Ramsdell, Joel W Sher, Melissa D. Carr-Reynolds, Elizabeth M. Hall, Sadie Lee, Cagan Gurer, Qikai Xu, Yifan Wang, Antoine J. Boudot, Ribhu Nayar, Gavin MacBeath TScan Therapeutics, Waltham, MA

Cells


1000-


Introduction

Human papilloma virus (HPV) is an oncogenic virus responsible for over 90% of cervical and anal cancers and over 25% of head and neck cancers, which are typically incurable upon metastasis. HPV E7 oncoprotein is a compelling target for TCR-engineered T cell therapy as it is homogenously expressed in every tumor cell, essential for tumor cell survival, and not expressed by healthy tissues. Notably, a recent clinical trial of an E7-directed TCR-T cell therapy conducted at the National Cancer Institute (NCI) showed a 50% objective response rate in heavily pre-treated patients with HPV+ cancers (1).

Using TScan's proprietary ReceptorScan platform, we discovered 453 putative HPV16 E7₁₁₋₁₉-specific TCRs by screening 681 million naïve CD8+ T cells from 15 unique healthy donors. We tested each TCR for expression in primary T cells and for its ability to kill T2 cells pulsed with the E7₁₁₋₁₉ peptide, using the NCI TCR as a benchmark for these studies (2). The top 3 TCRs from this screen were evaluated in depth for cytotoxicity, cytokine production, and T cell proliferation in response to a panel of HPV16+ cancer cell lines expressing varying levels of HLA-A*02:01 and E7. A lead TCR was identified that showed comparable activity relative to the NCI TCR. The lead TCR was evaluated for allo-reactivity using an array-based screen and for off-target reactivity using our proprietary SafetyScan platform, which is a highly $\frac{3}{2}$ 2500sensitive screen for off-target recognition based on supraphysiologic expression of protein fragments that span the entire human proteome. No alloreactivity was observed to 108/110 HLAs tested, and only a few putative off-targets were identified. The TCR-T cells showed no reactivity to a panel of normal primary human cells. including cells that naturally express the putative off-targets identified in the SafetyScan screen. In vivo studies in immunocompromised mice showed efficient control of xenogeneic tumor cell growth by TCR-200-A02 cells in two independent tumor models.

To further enhance the activity of our T cells, we designed a transposon-based vector that delivers the TCR gene, along with the genes for CD8 α/β and a dominantnegative form of TGF β RII, into both CD4+ and CD8+ T cells. We have advanced the resulting autologous TCR-T cell therapy candidate, TSC-200-A02, to IND-enabling studies. These results validate the use of *ReceptorScan*, in conjunction with SafetyScan, as a way to rapidly identify naturally occurring, high affinity TCRs that are suitable for clinical development.






Pan T cells (natural mixture of CD4+ and CD8+ T cells) were transduced to express HPV16 E7₁₁₋₁₉-specific TCRs and assessed for functional responses to target cells. (A) TCR-200-A02 shows efficient surface expression of TCR-200 (HPV16 E7₁₁₋₁₉specific dextramer) and Q-tagged CD8 α (QBEnd/10). (B) TCR-200-A02 efficiently secretes cytokines when co-cultured with SCC152 cells. (C) TCR-200-A02 exhibits HPV16-specific CD8+ and CD4+ T cell proliferation when co-cultured with SCC152 cells. (D) TCR-200-A02 shows strong cytotoxicity in HLA-A*02:01+ HPV16+ target cell lines CaSki, SCC152, SCC090, and no reactivity to HLA-A*02:01- HPV16+ cell line SiHa or the HLA-A*02:01+ HPV16- cell line NCI-H1792. TCRs were compared by one-way ANOVA followed by Dunnett's multiple comparison test. Differences that were non-significant (ns) are shown; all other differences were significant with P<0.05. Data are representative of 3 unique donors.


TCR-200-A02 shows no alloreactivity to 108/110 HLAs tested


most frequent class I MHCs in the US population.

TScan's genome-wide SafetyScan screen identifies putative off-targets for TCR-200-A02

(A) Overview of TScan's proprietary genome-wide SafetyScan screen. (B) SafetyScan screen of TCR-200-A02 identifies seven potential off-targets in a screen of >600,000 protein fragments spanning every w.t. human protein. The screen is designed to overpredict offtargets by overexpressing 90-aa protein fragments, which are more efficiently full-lenath proteins than Putative off-targets are identified by gene names. XM 0017722256 maps to the heterochromatic centromere region chromosome 20 and has been removed from the RefSeq annotation indicating a lack of evidence for its expression. No expression of this gene was detected using RNA-seq analysis of 51 samples including normal tissue samples, cancer cell lines and tumor samples.









NCG mice were subcutaneously inoculated with either 1x10⁶ CaSki or SCC152. When tumors reached 95 \pm 15 mm³ on Day 10, the mice were randomized and treated on Day 11 with 20x10⁶ cells of TCR-200-A02, non-transduced (NTD) cells or vehicle. (A & B) Treatment with TCR-200-A02 showed significant inhibition of tumor growth in vivo. (C & D) Individual mouse tumor growth per group over time. *p<0.05, One-way ANOVA, Holms-Šidák correction for multiple comparisons test in vivo.





Dominant negative TGFβ Receptor II (DN-TGFβRII) renders TSC-200-A02 resistant to TGFβ-mediated suppression. T cells were co-transduced with lentivirus encoding TCR-200-A02 and DN-TGFBRII and were FACS sorted into DN-TGFBRII positive and DN-TGFβRII negative fractions. Intracellular IFNγ within the TSC-200-A02 expressing cells was quantified after 24 h co-culture with peptide-pulsed T2 cells in the presence or absence of 5 ng/mL TGFβ.



Primary cells or iPSC-derived cells from healthy HLA-A*02:01+ human donors naturally expressing off-targets identified in the genome wide SafetyScan screen were co-cultured with TCR-200-A02 or nontransduced (NTD) cells. Cell pulsed with E7 peptide served as positive controls. IFNy secretion in culture supernatants was used as a read-out of TCR-200-A02 reactivity to target cells. SCC152 cells were used as a positive control and NCI-H1792 cells were used as a negative control

1. Nagarsheth NB, Norberg SM, Sinkoe AL, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021 Mar;27(3):419-425. 2. Jin BY, Campbell TE, Draper LM, et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight. 2018;3(8): e99488



TGF³RII-DN provides resistance to the suppressive effect of TGFβ signaling